This article was originally published in The Rose Sheet
Executive SummaryEuropean Commission "expect[s] decisive progress to be achieved before the end of the year" on the implementation of the Registration, Evaluation and Authorization of Chemicals program, with the first European Parliament reading of the proposal anticipated in November, VP Gunter Verheugen says in recent letter to Greenpeace. Letter responds to concerns by the environmental group over the ability of the chemicals program to protect consumers. Verheugen notes that final version of REACH must include "pragmatic solutions" to several feasibility issues that have arisen since the proposal was introduced in 2003...
You may also be interested in...
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products
Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.
Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.